You do not currently have access to this content.
Abstract. Activating mutations in the epidermal growth factor receptor (EGFR) gene occur in 10-20% of Caucasian and 40% of Asian non-small cell lung cancer (NSCLC) patients. Predominant ones among ...
AbstractBackground:. Urothelial carcinoma (UC) affects over 600,000 patients worldwide annually, with the incidence rate increasing over the past decade. Metastatic urothelial carcinoma (mUC) has a ...
Abstract. KSQ-001EX is an engineered TIL (eTIL) therapy with CRISPR/Cas9-mediated inactivation of SOCS1, a negative regulator of cytokine signaling and T cell function. SOCS1 was identified in a ...
Abstract. PD-L1 is an established immunotherapy target highly expressed in various solid tumors, while B7-H3 is another extensively investigated target overexpressed on a wide range of tumor cells.
AbstractIntroduction:. Trophoblast cell-surface antigen 2 (Trop-2) has become an attractive antibody drug conjugate (ADC) target as it is expressed in multiple solid tumors. Sacituzumab govitecan (SG) ...
Abstract. The identification of immunogenic cancer epitopes, including patient-specific neoepitopes and shared tumor-associated antigens (TAAs), is a critical foundation for advancing effective cancer ...
Around 75% of breast cancer (BC) patients have tumors expressing the treatment-predictive biomarker estrogen receptor α (ER) and are consequently offered endocrine therapy. One-third of these patients ...
Abstract. Advances in cancer prevention, early detection, and treatment have led to substantial improvements in cancer outcomes in the United States over the past several decades. Despite this ...
Background: GDF15 is overexpressed in solid tumors, with immunosuppressive effects on dendritic cells (DCs), T cells and myeloid-derived suppressor cells (MDSCs) in the tumor microenvironment. AZD8853 ...
CRISPR screens are a powerful discovery engine for biological research and have been extensively used for drug target discovery and validation. Pooled screens are advantageous because they can easily ...
JNJ-95437446 is a potential best-in-class EGFR/MET bispecific antibody drug conjugate designed to deliver a cytotoxic payload to tumor cells while leveraging the unique characteristics of amivantamab.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results